Australia markets closed

BridgeBio Pharma, Inc. (BBIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.79-0.16 (-0.64%)
As of 11:48AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 4.61B
Enterprise value 5.91B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)437.03
Price/book (mrq)N/A
Enterprise value/revenue 635.46
Enterprise value/EBITDA -10.45

Trading information

Stock price history

Beta (5Y monthly) 1.03
52-week change 357.12%
S&P500 52-week change 321.23%
52-week high 344.32
52-week low 312.75
50-day moving average 330.69
200-day moving average 330.61

Share statistics

Avg vol (3-month) 31.71M
Avg vol (10-day) 31.52M
Shares outstanding 5184.45M
Implied shares outstanding 6188.4M
Float 8113.02M
% held by insiders 15.37%
% held by institutions 192.16%
Shares short (28 Mar 2024) 414.28M
Short ratio (28 Mar 2024) 47.45
Short % of float (28 Mar 2024) 412.19%
Short % of shares outstanding (28 Mar 2024) 47.74%
Shares short (prior month 29 Feb 2024) 413.64M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-10,123.90%

Management effectiveness

Return on assets (ttm)-64.07%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)9.3M
Revenue per share (ttm)0.06
Quarterly revenue growth (yoy)-6.70%
Gross profit (ttm)N/A
EBITDA -592.95M
Net income avi to common (ttm)-643.2M
Diluted EPS (ttm)-3.95
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)434.88M
Total cash per share (mrq)2.47
Total debt (mrq)1.74B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.32
Book value per share (mrq)-7.74

Cash flow statement

Operating cash flow (ttm)-527.72M
Levered free cash flow (ttm)-249.07M